UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine

Reynolds, John A; Gayed, Mary; Khamashta, Munther A; Leone, Francesca; Toescu, Veronica; Bruce, Ian N; Giles, Ian; ... Gordon, Caroline; + view all (2022) Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology , 62 (3) pp. 1124-1135. 10.1093/rheumatology/keac372. Green open access

[thumbnail of Giles_Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine_VoR.pdf]
Preview
Text
Giles_Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine_VoR.pdf

Download (330kB) | Preview

Abstract

OBJECTIVES: Hydroxychloroquine (HCQ) and azathioprine (AZA) are used to control disease activity and reduce risk of flare during pregnancy in patients with SLE. The aim of this study was to determine outcomes of children born to mothers with SLE exposed to HCQ or AZA during pregnancy and breast-feeding. METHODS: Women attending UK specialist lupus clinics with children ≤17 years old, born after SLE diagnosis, were recruited to this retrospective study. Data were collected using questionnaires and from clinical record review. Factors associated with the outcomes of low birth weight and childhood infection were determined using multivariable mixed effects logistic regression models. RESULTS: We analysed 284 live births of 199 mothers from 10 UK centres. The first pregnancies of 147/199 (73.9%) mothers was captured in the study. 150/248 (60.4%) and 87 (31.1%) children were exposed to HCQ and AZA respectively. There were no significant differences in the frequency of congenital malformations or intrauterine growth restriction (IUGR) between children exposed or not to HCQ or AZA. AZA use was increased in women with a history of hypertension or renal disease. Although AZA was associated with low birth weight in univariate models, there was no significant association in multivariable models. In adjusted models, exposure to AZA was associated with increased reports of childhood infection requiring hospital management (OR 2.283 [1.003, 5.198], p= 0.049). CONCLUSIONS: There were no significant negative outcomes in children exposed to HCQ in pregnancy. AZA use was associated with increased reporting of childhood infection which warrants further study.

Type: Article
Title: Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1093/rheumatology/keac372
Publisher version: https://doi.org/10.1093/rheumatology/keac372
Language: English
Additional information: © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/).
Keywords: HCQ, AZA, SLE, pregnancy, adverse outcomes
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10165807
Downloads since deposit
135Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item